Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia

Research output: Contribution to journalArticle

Abstract

Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.

Original languageEnglish
Pages (from-to)575-583
Number of pages9
JournalNippon rinsho. Japanese journal of clinical medicine
Volume66
Issue number3
Publication statusPublished - 2008 Mar

Fingerprint

Aplastic Anemia
Stem Cell Transplantation
Transplantation
Stem Cells
Survival Rate
Myelodysplastic Syndromes
Anemia
Siblings
Early Diagnosis
Bone Marrow
Quality of Life
Tissue Donors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{eef30632cb12439d9f81a69ef959986e,
title = "Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia",
abstract = "Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40{\%} to more than 80{\%}. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.",
author = "Shinichiro Okamoto",
year = "2008",
month = "3",
language = "English",
volume = "66",
pages = "575--583",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia

AU - Okamoto, Shinichiro

PY - 2008/3

Y1 - 2008/3

N2 - Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.

AB - Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=42449102709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449102709&partnerID=8YFLogxK

M3 - Article

C2 - 18326329

AN - SCOPUS:42449102709

VL - 66

SP - 575

EP - 583

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -